Markets are Closed
Company Logo
GILD
Gilead Sciences Inc.

Open

Previous Open

High

64.63

Previous High

Low

63.33

Previous Low

Close

63.84

Previous Close

Volume

9,238,834

Previous Volume

Company Profile

Description

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Exchange

Nasdaq Global Select

List Date

January 03, 1994

CEO

John F. Milligan

Employees

10,000

Financials

Revenue

22.44B

Earnings

6.17B
35B
28B
21B
14B
7B
2015
2016
2017
2018

Splits

January 28, 20130.50%
June 25, 20070.50%
September 07, 20040.50%
March 08, 20020.50%
February 22, 20010.50%

Dividends

March 30, 2021$0.71
December 30, 2020$0.68
September 29, 2020$0.68
June 29, 2020$0.68
March 30, 2020$0.68
December 30, 2019$0.63
September 27, 2019$0.63
June 27, 2019$0.63
March 28, 2019$0.63
December 28, 2018$0.57
September 27, 2018$0.57
June 28, 2018$0.57
March 29, 2018$0.57
December 28, 2017$0.52
September 28, 2017$0.52
June 29, 2017$0.52
March 30, 2017$0.52
December 29, 2016$0.47
September 29, 2016$0.47
June 29, 2016$0.47
March 30, 2016$0.43
December 30, 2015$0.43
September 29, 2015$0.43
June 29, 2015$0.43

Related News

News post image: Duke University Hospital to test potential COVID-19 treatment on patients
Duke University Hospital to test potential COVID-19 treatment on patients
Mar 26, 2020 @ 11:08
As the world continues the search for potential treatments and vaccines to stem the COVID-19 pandemic, Duke University Hospital has announced some of its patients will be enrolled in a national trial for a leading treatment option....
finance yahoo
News post image: Drugmaker Gilead backpedals on specialty status for COVID-19 drug
Drugmaker Gilead backpedals on specialty status for COVID-19 drug
Mar 25, 2020 @ 20:51
Facing public criticism, the maker of a promising coronavirus drug said Wednesday it will waive a special regulatory designation that could have allowed it to block competition and boost profits for its treatment....
finance yahoo
News post image: Covid Report: Gilead Asks FDA To Rescind Key Status For Coronavirus Drug
Covid Report: Gilead Asks FDA To Rescind Key Status For Coronavirus Drug
Mar 25, 2020 @ 20:15
Shares of GILD stock slumped Wednesday after the biotech asked the Food and Drug Administration to rescind an orphan drug designation for its coronavirus treatment, dubbed remdesivir....
finance yahoo
News post image: Gilead pulls back 'orphan drug' request for experimental COVID drug
Gilead pulls back 'orphan drug' request for experimental COVID drug
Mar 25, 2020 @ 18:40
The Foster City-based company had faced criticism from Sen. Bernie Sanders and others about the designation, which would carry tax benefits and expand exclusivity for its experimental COVID-19 drug....
finance yahoo
News post image: Gilead asks FDA to revoke orphan drug status for potential coronavirus drug
Gilead asks FDA to revoke orphan drug status for potential coronavirus drug
Mar 25, 2020 @ 17:47
Gilead Sciences Inc said on Wednesday it had requested the U.S. Food and Drug administration to rescind the "orphan drug" status for its experimental drug, remdesivir, seen as one of the more promising potential treatments for the coronavirus. The drugmaker said it was confident of maintaining...
finance yahoo
News post image: Hoarding Chloroquine Won't Cure Coronavirus
Hoarding Chloroquine Won't Cure Coronavirus
Mar 25, 2020 @ 11:00
(Bloomberg Opinion) -- The need for any kind of  treatment to help stem the coronavirus outbreak is acute as cases and hospitalizations continue to mount. But there's a strong need to balance urgency and evidence.President Donald Trump's cheerleading of chloroquine and its derivative hydroxychloroquine...
finance yahoo
News post image: Gilead asks to rescind special status for potential coronavirus drug
Gilead asks to rescind special status for potential coronavirus drug
Mar 25, 2020 @ 07:08
Gilead Sciences has asked US regulators to rescind “orphan drug” status for its potential coronavirus treatment, after it was criticised by activists for abusing a process reserved for medicines for rare diseases. The company’s unusual U-turn on its potential coronavirus candidate Remdesivir comes just two days after Gilead disclosed it had been granted the status by the US Food and Drug Administration. Orphan drugs are intended for diseases affecting up to 200,000 people in the US....
finance yahoo
News post image: Gilead Sciences Jumps Higher After FDA Gives Coronavirus Treatment 'Orphan Drug' Status
Gilead Sciences Jumps Higher After FDA Gives Coronavirus Treatment 'Orphan Drug' Status
Mar 24, 2020 @ 13:37
The FDA's Orphan Drug status gives Gilead's remdesivir, a nascent coronavirus treatment, incentives for faster clinical trials and years of exclusivity....
finance yahoo
News post image: Singapore scientists study genes to fast-track coronavirus vaccine
Singapore scientists study genes to fast-track coronavirus vaccine
Mar 24, 2020 @ 07:06
Scientists in Singapore say they have developed a way to track genetic changes that speeds testing of vaccines against a coronavirus that has killed more than 16,000 people worldwide. The scientists, at the city-state's Duke-NUS Medical School, say their technique needs just days to evaluate potential...
finance yahoo
News post image: Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 23%?
Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 23%?
Feb 20, 2020 @ 12:44
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc......
finance yahoo
All data provided on Polygon is provided for informational purposes only, and is not intended for trading or investing purposes.
Copyright © 2021, Polygon.io, Inc. All Rights Reserved.
TradingView Lightweight Chart: Copyright (с) 2020 TradingView, Inc. https://www.tradingview.com/